Last checked at 5 May 2021 11:14
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Notice of Change of AGM Venue and Updated Dividend Timetable
Further to the announcement on 23 April 2021, EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces a change in venue of its Annual General Meeting ('AGM'), which will now take place at Harwood Capital, 6 Stratton Street, Mayfair, W1J 8LD on 19 May 2021 at 10.30am.
As previously announced, the Company is providing a facility for shareholders to join the AGM either online or telephonically and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 10.30 a.m. 17 May 2021.
To register for dial-in details and to submit any questions please contact Walbrook PR via email at ekf@walbrookpr.com or call +44 (0)20 7933 8787
No other details have changed.
Shareholders are reminded that due to the UK Government restrictions on public gatherings as a consequence of the COVID-19 pandemic, it will not be possible for shareholders to attend the AGM in person. The Board, with this in mind and in accordance with the Corporate Insolvency and Governance Act 2020, has therefore decided that the AGM will be held as a 'closed' meeting with the minimum number of Directors and officers who hold shares, present, to form the necessary quorum. Regrettably, other shareholders will not be permitted to attend the meeting in person.
Copies of the Annual Report and Accounts and Notice of AGM are available on the Company's website here: https://www.ekfdiagnostics.com/documents-reports.html
Updated Dividend Timetable
Further to the announcement of its final year results released on 30 March 2021, and subject to shareholder approval at the upcoming AGM, the dividend payment to shareholders of 1.1 pence per ordinary share will be made in accordance with the following timetable:
Ex-dividend date | 4 November 2021 |
Record date | 5 November 2021 |
Payment date | 1 December 2021 |
EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | |
Christopher Mills, Non-executive Chairman | Tel: +44 (0) 29 2071 0570 | |
Julian Baines, CEO | ||
Richard Evans, FD & COO | ||
N+1 Singer | Tel: 020 7496 3000 | |
Aubrey Powell / George Tzimas / Tom Salvesen | ||
Walbrook PR Limited | Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com | |
Paul McManus / Lianne Cawthorne | Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303 | |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.
EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products.